Skip to main content
Clinical Trials/NCT02146794
NCT02146794
Completed
Phase 1

Renal Denervation in Chronic Heart Failure

Imperial College London0 sites7 target enrollmentMay 2011
ConditionsHeart Failure

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Imperial College London
Enrollment
7
Primary Endpoint
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

Renal denervation can be carried out for heart failure

Detailed Description

There are theoretical reasons why renal denervation might be beneficial for patients with chronic heart failure. It is not known whether they would suffer large drops in blood pressure which might compromise safety. This pilot study required patients to remain in hospital for one week during which they had careful monitoring of blood pressure with the ability to halt the trial if any patient suffered any dangerous effect such as a large drop in blood pressure. It also monitored blood pressure after discharge for six months.

Registry
clinicaltrials.gov
Start Date
May 2011
End Date
February 2012
Last Updated
11 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients were required to have chronic symptomatic systolic heart failure (NYHA class III or IV) on maximal tolerated medical therapy, including beta-blocker, ACE inhibitor or angiotensin receptor blocker, and spironolactone.

Exclusion Criteria

  • Clinically unstable patients or those with significant valvular disease
  • An estimated glomerular filtration rate \<35 ml/min
  • Unfavourable renal anatomy
  • Tortuous femoral arteries were not eligible

Outcomes

Primary Outcomes

Number of Participants with Adverse Events as a Measure of Safety and Tolerability

Time Frame: 6 months

Renal denervation had been reported to cause a 30 mmHg fall in blood pressure when used in hypertension. Although in principle renal denervation might be favourable for physiology in chronic heart failure, numerous theoretical possibilities exist for the procedure causing deterioration in clinical status, including the possibility of a large fall in blood pressure. A deterioration in symptomatic status or occurrence of an event such as presyncope or syncope would be considered a primary outcome event.

Secondary Outcomes

  • Systolic blood pressure(6 months)
  • Serum Creatinine(6 months)
  • Serum sodium(6 months)
  • Serum potassium(6 months)
  • 6 minute walk distance(6 months)

Similar Trials